Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

Circulating tumour DNA (ctDNA) is a potential biomarker that could contribute to more
judicious patient selection for personalised treatment. This review and meta-analysis gives …

Introduction Colorectal cancer is a leading cause of cancer-related death worldwide.
Metastatic liver disease develops in 50% of cases and drives patient outcomes. Although the …

Introduction Patients who recur in the first year after resection of colorectal liver metastases
(CRLM) do poorly. The aim of our study was to predict treatment failure in patients …

Purpose We investigated the potential clinical utility of short-term serial KRAS-mutated
circulating cell-free tumor DNA (ctDNA) assessment for predicting therapeutic response in …

Purpose Nearly one-third of patients diagnosed with colorectal cancer (CRC) will ultimately
develop metastatic disease. While a small percentage of patients can be considered for …

Background For patients with colorectal liver metastases (CRLM) who receive neoadjuvant
therapy (NAT), reliable indicators that can early and accurately predict treatment response …

PURPOSE Liver metastases occur in about 50% of colorectal cancer cases and drive patient
outcomes. Circulating tumor DNA (ctDNA) is emerging as a diagnostic, surveillance, and …

Summary Background Circulating tumour DNA (ctDNA)-based molecular residual disease
(MRD) detection technology has been widely used for recurrence evaluation, but there is no …

Purpose: Minimal residual disease (MRD) detection can identify the recurrence in patients
with colorectal cancer (CRC) following definitive treatment. We evaluated a plasma-only …